Lexeo Therapeutics (LXEO) Operating Expenses (2022 - 2026)

Lexeo Therapeutics' Operating Expenses history runs 5 years deep, the most recent figure standing at $22.3 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 33.94% year-over-year to $22.3 million; the TTM figure through Mar 2026 stood at $97.8 million (down 15.91% YoY), while the FY2025 annual figure was $109.3 million, up 3.3% from the prior year.
• Operating Expenses came in at $22.3 million for Q1 2026 at Lexeo Therapeutics, down from $23.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $33.8 million in Q1 2025 to a low of $14.0 million in Q2 2023.
• A 5-year average of $22.6 million and a median of $22.3 million in 2026 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 82.86% in 2024 and plunged 33.94% in 2026, its largest moves.
• Lexeo Therapeutics' Operating Expenses stood at $15.2 million in 2022, then decreased by 1.47% to $15.0 million in 2023, then jumped by 82.86% to $27.4 million in 2024, then fell by 15.58% to $23.1 million in 2025, then decreased by 3.39% to $22.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $22.3 million, $23.1 million, and $21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison